BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 8424417)

  • 1. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis.
    Chang F; Syrjänen S; Kurvinen K; Syrjänen K
    Am J Gastroenterol; 1993 Feb; 88(2):174-86. PubMed ID: 8424417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [P53 and cancers].
    May P; May E
    Pathol Biol (Paris); 1995 Mar; 43(3):165-73. PubMed ID: 7675543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumourigenesis associated with the p53 tumour suppressor gene.
    Chang F; Syrjänen S; Tervahauta A; Syrjänen K
    Br J Cancer; 1993 Oct; 68(4):653-61. PubMed ID: 8398688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressor genes.
    Levine AJ
    Bioessays; 1990 Feb; 12(2):60-6. PubMed ID: 2140509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 from basic research to clinical applications.
    Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
    Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The p53 gene and protein in 2005: new results, promising opportunities].
    Szoke D; Sipos F; Spisák S; Molnár B; Tulassay Z
    Orv Hetil; 2005 Jul; 146(30):1587-94. PubMed ID: 16136736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the p53 gene occur in diverse human tumour types.
    Nigro JM; Baker SJ; Preisinger AC; Jessup JM; Hostetter R; Cleary K; Bigner SH; Davidson N; Baylin S; Devilee P
    Nature; 1989 Dec; 342(6250):705-8. PubMed ID: 2531845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
    Mendoza-Rodríguez CA; Cerbón MA
    Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of genes whose expressions are altered in rat 6 fibroblasts transformed by mutant p53(val135).
    Yam JW; Zheng JY; Hsiao WL
    Biochem Biophys Res Commun; 1999 Dec; 266(2):472-80. PubMed ID: 10600527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Methylcholanthrene triggers the differentiation of alveolar tumor cells from canine bronchial basal cells and an altered p53 gene promotes their clonal expansion.
    TenHave-Opbroek AA; Shi XB; Gumerlock PH
    Carcinogenesis; 2000 Aug; 21(8):1477-84. PubMed ID: 10910947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
    Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
    Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor suppressor gene p53--function and significance in gastroenterology].
    Schoppmeyer K; Keim V; Mössner J
    Z Gastroenterol; 1997 Jun; 35(6):491-509. PubMed ID: 9281241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53: an overview of over two decades of study.
    Cheah PL; Looi LM
    Malays J Pathol; 2001 Jun; 23(1):9-16. PubMed ID: 16329542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.
    Harris MP; Sutjipto S; Wills KN; Hancock W; Cornell D; Johnson DE; Gregory RJ; Shepard HM; Maneval DC
    Cancer Gene Ther; 1996; 3(2):121-30. PubMed ID: 8729911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutants with changes in conserved region II: three classes with differing antibody reactivity, SV40 T antigen binding and ability to inhibit transformation of rat cells.
    Schmieg FI; Simmons DT
    Oncogene; 1993 Aug; 8(8):2043-50. PubMed ID: 8393158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin.
    Luo JL; Tong WM; Yoon JH; Hergenhahn M; Koomagi R; Yang Q; Galendo D; Pfeifer GP; Wang ZQ; Hollstein M
    Cancer Res; 2001 Nov; 61(22):8158-63. PubMed ID: 11719445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.